这一常见且令人困扰的疾病不仅影响美观——甚至症状非常轻微的患者也每天处于困扰中13。根据2003年至2011年国家银屑病基金会（NationalPsoriasis Foundation，NPF）对5,600例患者进行的调查分析，52%的轻、中和重度银屑病患者对其疾病管理并不满意17。在所调查的这些患者中，一些患者当时未接受任何治疗（9.4~49.2%）或者存在治疗不足的情况（10.2~55.5%）17。

参考资料

1.ThaciD, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab inclearing skin of subjects with moderate to severe plaque psoriasis: 16 weekresults from the CLEAR study. American Academy of Dermatology 73rd  Annual Meeitng.  San Francisco, California. 20th  March.

2.EuropeanMedicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)Guidelines on clinical investigation of medicinal products indicated for thetreatment of psoriasis. 2004. Availableat:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf    Accessed February 9, 2015.

3.Mrowietz,U. Implementing treatment goals for successful long-term management ofpsoriasis. Journal of the European Academy of Dermatology and Venereology, 26:12–20.doi: 10.1111/j.1468-3083.2011.04411.x

4.LangleyRG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis: results oftwo phase three trials. N Engl J Med. 2014. Jul 9;371(4):326-38.

5.BlauveltA, Prinz J, Gottlieb AB, et al. Secukinumab Administration by Pre-filledSyringe: Efficacy, Safety, and Usability Results from a Randomized ControlledTrial in Psoriasis (FEATURE).  Br JDermatol. 2014.  Dec 11; 172(2): 484–493.doi: 10.1111/bjd.13348

6.PaulC, Lacour JP, Tedremets L, et al. Efficacy, safety, and usability ofsecukinumab administration by autoinjector/pen in psoriasis: a randomized,controlled trial (JUNCTURE).  J Eur AcadDermatol Venereol. 2014.  Sep 22; doi:10.1111/jdv.12751

7.GaffenSL. Structure and signaling in the IL-17 receptor family.  Nat Rev Immunol. 2009;9(8):556-67.

8.IvanovS, Linden A. Interleukin-17 as a drug target in human disease.  Trends Pharmacol Sci. 2009;30(2):95-103.

9.KopfM, Bachmann MF, Marsland BJ. Averting inflammation by targeting the cytokineenvironment.  Nat Rev Drug Discov. 2010;9(9):703-18.

10.OnishiRM, Gaffen SL. Interleukin-17 and its target genes: mechanisms ofinterleukin-17 function in disease. Immunology. 2010;129(3):311-21.

11.KruegerJ, Fretzin S, Suárez-Fari?asM, et al. IL-17A is essential for cell activation and inflammatory genecircuits in subjects with psoriasis.  JAllergy Clin Immunol. 2012;130(1):145-154.

12.JohansenC, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17isoforms and receptors in lesional psoriatic skin.  Brit J Dermatol. 2009;160(2):319-24.

13.SternRS, Nijsten T, Feldman S, et al. Psoriasis Is Common, Carries a SubstantialBurden Even When Not Extensive, and Is Associated with Widespread TreatmentDissatisfaction.  J Investig DermatolSymp. 2004;9(2):136-9.Nestle FO, Kaplan DH, Barker J. Psoriasis.  N Engl J Med. 2009; 361(5):496-509.